LA JOLLA, Calif. – November 22, 2016 – Synthetic Genomics, Inc., announced today that Oliver Fetzer, Ph.D., chief executive officer, will present at two upcoming conferences.
- Piper Jaffray 28th Annual Healthcare Conference in New York City at 11:10 a.m. EST on Tuesday, November 29.
- Genetic Rx conference in Boston, as part of the “Next Generation RNA Technologies” panel, at 9:45 a.m. EST on Thursday, December 8.
About Synthetic Genomics
Synthetic Genomics, Inc., located in La Jolla, CA, is a leader in the fields of synthetic biology and synthetic genomics, advancing genomics to better life. Synthetic Genomics applies its intellectual property in this rapidly evolving field to design and build biological systems solving global sustainability challenges. Synthetic Genomics serves three end markets: research, bioproduction, and applied products. The company’s research offerings, commercialized through its subsidiary SGI-DNA, are revolutionizing science and medicine with next-generation genomic solutions, including the world’s first DNA printer. Synthetic Genomics applies its integrated synthetic biology capabilities to reinvent bio-based production by improving existing production systems and developing novel, optimized production hosts. Synthetic Genomics develops its applied products, typically in partnership with leading global organizations, across a variety of industries including sustainable bio-fuels, sustainable crops, nutritional supplements, vaccines, and transplantable organs.
Corporate Communications Contact
Canale Communications for Synthetic Genomics, Inc.